Study guide

20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid)

NBCRNA CRNA Certified Registered Nurse Anesthetist NCE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology

1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders

2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems

2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms

3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives

3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology

4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics

4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics

5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies

5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout

6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators

6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging

7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation

7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways

8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety

8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety

9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation

9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication

10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring

10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies

11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms

11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)

12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA

12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm

13 Chapter 13: Regional Anesthesia: Neuraxial Blocks

13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma

14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance

14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols

15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice

15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives

16 Chapter 16: Obstetric & Gynecologic Anesthesia

16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient

17 Chapter 17: Pediatric Anesthesia

17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm

18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia

18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols

19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia

19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction

20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia

20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation

21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology

21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements

22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology

22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices

23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures

23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases

24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control

24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure

25 Chapter 25: Neurosurgical Subspecialty Procedures

25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy

26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia

26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery

27 Chapter 27: Orthopedic & Extremity Anesthesia

27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block

28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy

28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia

29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients

29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient

20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid)

Key Takeaways Explain This Topic AI

CO₂ pneumoperitoneum during laparoscopy should be maintained at an intra-abdominal pressure (IAP) of 12 to 15 mmHg; insufflation increases SVR, MAP, and myocardial wall stress while decreasing venous return, cardiac index, and renal cortical blood flow.

Cephalad diaphragmatic shift during laparoscopy reduces FRC by 20% to 30%, increases peak airway pressures, and promotes dependent atelectasis; steep Trendelenburg positioning further exacerbates these changes and increases the risk of inadvertent right mainstem endobronchial intubation.

Pheochromocytoma mandates an inviolable preoperative pharmacologic sequence: complete alpha-adrenergic blockade (Phenoxybenzamine or Doxazosin for 10-14 days) MUST precede beta-adrenergic blockade to prevent unopposed alpha-1 vasoconstriction, catastrophic hypertensive crisis, and acute pulmonary edema.

Intraoperative pheochromocytoma management features two distinct hemodynamic crises: severe hypertensive surges during tumor manipulation (treated with Sodium Nitroprusside, Nicardipine, Clevidipine, and Magnesium Sulfate) followed by profound refractory vasoplegic shock upon tumor vein ligation (managed with aggressive volume loading, Vasopressin, and Norepinephrine).

Carcinoid crisis is triggered by tumor manipulation or sympathomimetic administration, releasing massive amounts of serotonin, bradykinin, and kallikrein; definitive management requires high-dose Octreotide (100-500 mcg IV bolus), while sympathomimetics (Ephedrine, Epinephrine) and histamine-releasing drugs are strictly contraindicated.

Last updated: August 2026

20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid)

Advanced intra-abdominal and endocrine tumor procedures present complex hemodynamic, ventilatory, and neurohumoral challenges. Anesthesia providers must anticipate the physiological consequences of laparoscopic CO₂ insufflation, prevent catastrophic hypertensive and vasoplegic crises during pheochromocytoma resection, and effectively manage carcinoid crises with targeted receptor pharmacology.

1. Laparoscopy & CO₂ Pneumoperitoneum Physiology

Laparoscopic surgery utilizes peritoneal insufflation with carbon dioxide ( C O 2 CO_2 C O 2 ​ ) to create a working space. Carbon dioxide is the preferred gas because it is non-flammable (permitting electrocautery/laser use), highly soluble in blood (rapidly absorbed and expired, minimizing the severity of gas embolism), and cleared efficiently by pulmonary ventilation. +---------------------------------------------------------------------------------------------------------+

  • | PHYSIOLOGICAL IMPACT OF CO₂ PNEUMOPERITONEUM |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | Organ System | Physiologic Alteration | Anesthetic Management & Impact |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Intra-Abdominal** | • Target working IAP: **12 - 15 mmHg**| • Pressures >15 mmHg severely compromise |
  • | **Pressure (IAP)** | • Compression of splanchnic/IVC beds | cardiac output and organ perfusion |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Systemic Hemodynam-**| • **SVR INCREASES (↑ 30 - 50%)** | • Mechanical aortic compression + release|
  • | **ics** | • **MAP & Afterload INCREASE** | of vasopressin, renin, catecholamines |
  • | | • **Cardiac Output DECREASES (↓ 10-30%)**| • IVC compression reduces venous return |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Cardiac Conduction**| • Peritoneal stretch triggers | • Treat severe bradycardia/asystole with |
  • | | **acute vagal reflex (bradycardia)**| immediate desufflation & glycopyrrolate|
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Renal Function** | • Renal vascular resistance ↑ | • Direct renal vein/parenchymal compress-|
  • | | • **GFR & Urine Output DECREASE** | ion; transient oliguria is expected |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Respiratory Mechan-**| • Diaphragm displaced cephalad | • Peak inspiratory pressures (PIP) ↑ |
  • | **ics** | • **FRC DECREASES by 20 - 30%** | • Pulmonary compliance ↓; atelectasis |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Arterial Blood Gas**| • Continuous systemic CO₂ absorption | • ETCO₂ rises, plateaus in 15-30 min; |
  • | | • Hypercapnia & respiratory acidosis | requires **20 - 30% ↑ in Minute Vent.**|

+-----------------------+--------------------------------------+------------------------------------------+ [HEMODYNAMIC PROFILE OF IAP ELEVATION]

  • Hemodynamic Parameter
  • ^
  • High| SVR / MAP / Afterload (↑↑)
  • | /---------------------------------
  • | /
  • | / Stroke Volume / Cardiac Output (↓↓)
  • | / /--------------------------------
  • Low+-------------+---+---------------------------------->
  • 0 10 15 25
  • Intra-Abdominal Pressure (IAP, mmHg)
  • Positioning Effects: Trendelenburg vs. Reverse Trendelenburg

Steep Trendelenburg (Pelvic / Lower GI / Robotic Urology):

Gravity pushes abdominal viscera cephalad against the diaphragm, further exacerbating FRC reduction, decreasing pulmonary compliance, and increasing peak inspiratory pressures.

Significantly increases central venous pressure (CVP), intracranial pressure (ICP), and intraocular pressure (IOP), elevating the risk of ischemic optic neuropathy (ION) and cerebral edema.

Airway Hazard: The carina shifts cephalad as the lungs are compressed, causing the fixed endotracheal tube to migrate deeper into the airway, resulting in unintentional right mainstem endobronchial intubation .

Reverse Trendelenburg (Upper GI / Bariatric / Cholecystectomy):

Improves diaphragmatic excursion and FRC, but promotes venous pooling in lower extremities, worsening the reduction in venous return and cardiac output induced by pneumoperitoneum.

Complication: CO₂ Gas Embolism

Etiology: Inadvertent direct placement of a Veress needle or laparoscopic trocar into a major intra-abdominal vessel (e.g., inferior vena cava, iliac vein, mesenteric vein) during high-flow insufflation.

Clinical Presentation: Sudden, catastrophic drop in end-tidal CO₂ (due to dead-space ventilation and RVOT vapor lock), acute pulmonary hypertension, cyanosis, severe hypotension, hypoxemia, and a "mill-wheel" murmur.

Emergency Management:

Immediately release the pneumoperitoneum (desufflate abdomen).

Discontinue nitrous oxide and administer 100% FiO₂ .

Place patient in Durant's position (Left Lateral Decubitus with Trendelenburg tilt) to trap the gas bubble in the right ventricular apex away from the pulmonary outflow tract.

Aspirate gas from a central venous catheter if present.

Initiate aggressive hemodynamic support and chest compressions if cardiac arrest occurs.

2. Pheochromocytoma: Pathophysiology & Preoperative Optimization

Pheochromocytomas are rare, highly vascular catecholamine-secreting neuroendocrine tumors derived from chromaffin cells of the adrenal medulla (85-90%) or extra-adrenal paraganglia (paragangliomas, 10-15%). They secrete variable ratios of norepinephrine (predominantly), epinephrine , and occasionally dopamine . +---------------------------------------------------------------------------------------------------------+

  • | PHEOCHROMOCYTOMA CLINICAL OVERVIEW |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | Diagnostic Domain | Clinical Findings | Key Associations & Confirmatory Tests |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Classic Triad** | 1. Paroxysmal / Episodic Headache | • Severe episodic hypertension |
  • | | 2. Profuse Diaphoresis (Sweating) | • Palpitations, tremulousness, pallor |
  • | | 3. Tachycardia / Palpitations | • Hyperglycemia (gluconeogenesis/glycog) |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Genetic Syndromes** | • MEN 2A & MEN 2B (RET proto-oncogene)| • Von Hippel-Lindau (VHL) disease |
  • | | • Neurofibromatosis Type 1 (NF1) | • Succinate dehydrogenase (SDH) mutations|
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Biochemical Tests** | • 24-hr urinary metanephrines/catech | • Fractionated plasma free metanephrines |
  • | | • Urinary Vanillylmandelic Acid (VMA)| (highest diagnostic sensitivity) |
  • +-----------------------+--------------------------------------+------------------------------------------+

The Inviolable Rule: Alpha-Blockade BEFORE Beta-Blockade +-------------------------------------------------------------------------+

  • | PREOPERATIVE PHARMACOLOGIC TIMELINE |
  • +-------------------------------------------------------------------------+
  • | STEP 1: INITIATE ALPHA-ADRENERGIC BLOCKADE (10 - 14 Days Preoperative) |
  • | • Drug of Choice: **Phenoxybenzamine** (irreversible, non-competitive |
  • | α₁ and α₂ blocker, 10 mg PO BID, titrated to 40-100 mg/day) or |
  • | selective α₁ blockers (**Doxazosin**, Prazosin, Terazosin) |
  • | • Goal: Expand contracted intravascular volume; restore vasodilation |
  • | • Clinical endpoints: Orthostatic hypotension, nasal congestion |
  • | |
  • | STEP 2: INITIATE BETA-ADRENERGIC BLOCKADE (2 - 3 Days Preoperative) |
  • | • Added ONLY AFTER complete alpha-blockade is established |
  • | • Indication: Treat reflex tachycardia or tachyarrhythmias |
  • | • Agents: Metoprolol, Atenolol, Labetalol, Esmolol |
  • +-------------------------------------------------------------------------+

NCE Fatal Exam Trap — The Unopposed Alpha Catastrophe: NEVER administer a beta-blocker prior to establishing complete alpha-adrenergic blockade. Beta-2 adrenergic receptors in skeletal muscle vascular beds mediate vasodilation. If a non-selective beta-blocker (or any beta-blocker) is given while vascular alpha-1 receptors remain unblocked, two fatal events occur:

Blockade of vasodilatory β 2 \beta_2 β 2 ​ receptors leaves circulating norepinephrine and epinephrine to act unopposed on vascular α 1 \alpha_1 α 1 ​ receptors, precipitating malignant vasoconstriction and catastrophic hypertensive crisis .

Blockade of myocardial β 1 \beta_1 β 1 ​ inotropic support prevents the left ventricle from overcoming the massive afterload spike, triggering acute left ventricular failure and flash pulmonary edema .

Roizen Criteria for Preoperative Adequacy

Blood pressure < 160 / 90 mmHg < 160/90 \text{ mmHg} < 160/90 mmHg consistently for at least 24 to 48 hours.

Orthostatic hypotension present (systolic blood pressure decrease > 10 mmHg >10 \text{ mmHg} > 10 mmHg upon standing, but standing systolic BP not < 80 − 90 mmHg <80 - 90 \text{ mmHg} < 80 − 90 mmHg ).

Absence of ST-T wave ischemic changes or new arrhythmias on 12-lead EKG for at least 1 to 2 weeks.

Fewer than 1 premature ventricular contraction (PVC) every 5 minutes.

3. Intraoperative Management of Pheochromocytoma +---------------------------------------------------------------------------------------------------------+

  • | INTRAOPERATIVE PHEOCHROMOCYTOMA PHASES |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | Operative Phase | Hemodynamic Threat | Pharmacologic Countermeasures |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **1. Pre-Induction &**| • Massive catecholamine surge from | • **Arterial Line placed BEFORE induction|
  • | ** Intubation** | laryngoscopy / intubation stimulus | • Deep plane of anesthesia (Fentanyl, |
  • | | • Tachycardia & hypertensive spike | Lidocaine, Propofol, Vecuronium) |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **2. Insufflation &** | • Direct tumor palpation dumps mass- | • **Sodium Nitroprusside** (arterial dil)|
  • | ** Tumor Manipula-**| ive norepinephrine/epi into blood | • **Nicardipine / Clevidipine** (CCB) |
  • | ** tion** | • SBP >250 mmHg, tachyarrhythmias | • **Phentolamine** (short-acting α-block)|
  • | | • Severe ventricular ectopy / VT | • **Esmolol** (short-acting β₁-block) |
  • | | | • **Magnesium Sulfate** (2-4 g IV bolus) |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **3. Post-Tumor Vein**| • Sudden withdrawal of catecholamines| • **Aggressive Intravascular Volume** |
  • | ** Ligation** | • Down-regulated vascular receptors | • **Vasopressin Infusion** (V₁ receptor) |
  • | | • Residual preop alpha-blockade | • **Norepinephrine / Epinephrine** |
  • | | • **Profound Vasoplegic Collapse** | • Calcium chloride for inotropic support |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • Drug Selection Rules for Pheochromocytoma

Drugs to AVOID:

Histamine-releasing agents (Morphine, Meperidine, Atracurium) → \rightarrow → histamine triggers catecholamine release from chromaffin granules.

Indirect-acting sympathomimetics (Ephedrine) → \rightarrow → releases endogenous norepinephrine stores.

Vagolytics & Arrhythmogenics (Atropine, Pancuronium, Ketamine, Halothane, Desflurane rapid concentration jumps).

Dopamine antagonists (Metoclopramide, Droperidol) → \rightarrow → can provoke hypertensive crisis by blocking presynaptic dopamine-mediated inhibition of catecholamine release.

Magnesium Sulfate in Pheochromocytoma:

Magnesium acts as a physiological calcium antagonist: it inhibits the exocytosis of catecholamines from adrenal chromaffin granules, reduces vascular smooth muscle responsiveness to catecholamines, and dilates peripheral arterioles without causing reflex tachycardia.

4. Carcinoid Syndrome & Carcinoid Crisis Management

Carcinoid tumors are neuroendocrine neoplasms arising from enterochromaffin (Kulchitsky) cells , most commonly in the gastrointestinal tract (ileum, appendix, rectum) and bronchopulmonary system. They synthesize and secrete serotonin (5-HT) , bradykinin , histamine , kallikrein , and prostaglandins . +-------------------------------------------------------------------------+

  • | CARCINOID PATHOPHYSIOLOGY & METASTASES |
  • +-------------------------------------------------------------------------+
  • | 1. Primary GI Carcinoid: Vasoactive substances drain into portal system |
  • | → 100% metabolized by hepatic monoamine oxidase (MAO) on first pass |
  • | → NO systemic carcinoid symptoms occur |
  • | |
  • | 2. Hepatic Metastases or Bronchial/Ovarian Carcinoid: |
  • | → Vasoactive mediators drain DIRECTLY into systemic circulation |
  • | → Bypasses hepatic metabolism → **CARCINOID SYNDROME MANIFESTS** |

+-------------------------------------------------------------------------+ +---------------------------------------------------------------------------------------------------------+

  • | CARCINOID SYNDROME CLINICAL FEATURES |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | Clinical Manifestation| Biochemical Mediator | Pathophysiology & Exam Findings |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Cutaneous Flushing**| Bradykinin, Histamine, Serotonin | • Episodic bright red/violaceous erythema|
  • | | | of the face, neck, and upper torso |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Secretory Diarrhea**| Serotonin (5-HT) | • Intractable watery diarrhea, cramps |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Bronchospasm** | Serotonin, Bradykinin, Histamine | • Severe wheezing, dyspnea, high PIP |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Right-Sided Heart** | Serotonin (fibroblast stimulation) | • **Tricuspid Regurgitation** |
  • | **Disease (Hedinger)**| | • **Pulmonary Valve Stenosis** |
  • | | | • **Left-sided valves SPARED** (pulmonary|
  • | | | endothelial MAO degrades serotonin) |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Diagnostic Marker** | **24-hour urinary 5-HIAA** | • End product of serotonin metabolism |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • Carcinoid Crisis: Emergency Rescue Pharmacology

Carcinoid crisis is a life-threatening oncologic emergency precipitated by tumor manipulation, anesthesia induction, hypothermia, hypoxia, or catecholamine administration. It manifests as refractory, profound hypotension (or occasionally severe hypertension), intense flushing, intractable bronchospasm, and ventricular arrhythmias. +---------------------------------------------------------------------------------------------------------+

  • | CARCINOID CRISIS MANAGEMENT PROTOCOL |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | Strategy | Drug & Dosage | Mechanism & Clinical Rationale |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **FIRST-LINE DRUG OF**| **Octreotide (Sandostatin)** | • Synthetic somatostatin analog that spe-|
  • | **CHOICE (RESCUE)** | **100 - 500 mcg IV Bolus** | cifically inhibits exocytosis of sero- |
  • | | Followed by **50 - 200 mcg/hr** inf. | tonin, bradykinin, and gut peptides |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Vasopressor of** | **Vasopressin** or **Phenylephrine** | • Direct V₁ / α₁ vasoconstriction |
  • | **Choice (if needed)**| | • Does NOT stimulate tumor release |
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **CONTRAINDICATED** | **Ephedrine, Epinephrine, Isoproter-**| • **STRICTLY PROHIBITED:** Beta-agonism |
  • | **DRUGS** | **enol, Dopamine, Norepinephrine** | stimulates tumor adenylate cyclase, |
  • | | | triggering massive paradoxical release |
  • | | | of serotonin/bradykinin (worsens shock)|
  • +-----------------------+--------------------------------------+------------------------------------------+
  • | **Avoid Histamine** | Morphine, Meperidine, Atracurium | • Histamine triggers mediator cascade |
  • | **Releasers** | | |
  • +-----------------------+--------------------------------------+------------------------------------------+

Loading diagram... Laparoscopic and Endocrine Tumor Anesthetic Pathways